Zhenyuan pharmaceutical is expected to obtain production approval for ademetionine succinate in about one month

Adenosylmethionine succinate, a new hepatobiliary drug from Zhenyuan, Zhejiang Province, and its injection status have been changed to "under approval" The company is expected to obtain the production approval document in about one month At that time, it will share the domestic market with Abbott and Haizheng pharmaceutical industry In late March of this year, the adenosylmethionine products declared for production by Zhejiang Zhenyuan had become "under examination and approval" However, due to the requirement of the drug regulatory bureau that the generic name of adenosylmethionine products need to be modified in accordance with the normative requirements, the product declaration status was returned to "under review" At present, the relevant requirements have been modified and the product review process has returned to normal According to the official website of Zhenyuan pharmaceutical, a subsidiary of Zhejiang Zhenyuan, ademetionine succinate was developed by the company in 2004 Up to now, the company has invested tens of millions of yuan in R & D and supporting production equipment system costs If it is approved for listing, it is likely to become a heavyweight NEW strategic product Data show that adenosylmethionine is a kind of physiologically active molecule commonly existing in human tissues and body fluids, which is mainly suitable for intrahepatic cholestasis and intrahepatic cholestasis in pregnancy before and after cirrhosis, and can make the abnormal liver function caused by various reasons turn to normal It is reported that in 2013, the sales revenue of ademetionine succinate injection of Haizheng pharmaceutical, the first pharmaceutical imitator, reached 167 million yuan, accounting for more than one third of the market.